Previous 10 | Next 10 |
The FDA Breakthrough Therapy Designation (BTD) was an offshoot of the Food and Drug Administration Safety and Innovation Act (FDASIA) that was signed on July 9, 2012 , that called for a new designation to be created. Since 2012, only 147 drugs have been approved having this designation, which...
Shares of Dicerna Pharmaceuticals (NASDAQ: DRNA) fell more than 11% today for no apparent reason. However, individual investors who have been following the biopharma know that the stock has erupted higher in the second half of 2019. Shares have gained 63% in the last three months -- and that...
Gainers: Marinus Pharmaceuticals (NASDAQ: MRNS ) +42% . More news on: Marinus Pharmaceuticals, Inc., Prothena Corporation plc, Applied Genetic Technologies Corporation, Stocks on the move, Read more ...
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the successful closing of the research collaboration and licensing agreeme...
Some investors may well believe that Alnylam ( ALNY ) had already de-risked its lumasiran program for primary hyperoxaluria Type 1 (or PH1) with strong Phase II and open-label extension study data, but there is a reason that the FDA requires pivotal studies, and Alnylam came through with stron...
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the European Commission (EC) has granted orphan drug designation to D...
– Option Exercise Triggers $20 Million Payment to Dicerna – Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA) today announced that Alexion has exercised its option for exclusive rights to two additional targets within th...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on multiple discriminant analysis ((MDA)) breakout selections over more than five years. This subset of the different portfolios I regularly analyze has now reached 135 weeks of public selections as part of t...
Today, we will be studying why Dicerna Pharmaceuticals ( DRNA ) is an attractive investment for 2020. Company overview Dicerna Pharmaceuticals is a small-cap biopharmaceutical company focused on developing innovative RNAi (RNA interference) therapies. The company is predominantly targeti...
The following slide deck was published by Dicerna Pharmaceuticals, Inc. in conjunction with this Read more ...
News, Short Squeeze, Breakout and More Instantly...
Dicerna Pharmaceuticals Inc. Company Name:
DRNA Stock Symbol:
NASDAQ Market:
Dicerna Pharmaceuticals Inc. Website:
Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. (Dicerna; Nasdaq: DRNA), announced on 18 November 2021, has been completed. Following the expiration of Novo Nordisk’s cash tender offer for Dicerna, Novo Nordisk has today acquired all outstan...
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Novo Nordisk’s cash tender offer for Dicerna expired at 11:59 p.m., Easter...
Direxion Launches mRNA ETF (MSGR) MSGR Offers Exposure to Rapidly Evolving mRNA Sector PR Newswire NEW YORK , Dec. 9, 2021 /PRNewswire/ -- Direxion announced today the launch of the Direxion mRNA ETF (Ticker: MSGR) . MSGR invests in companies ...